March 21, 2021
Article
A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.
Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.
March 20, 2021
In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,
Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.
Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.
A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels
March 26, 2019
An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.
March 25, 2019
No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.
Over the course of 16 weeks, OSA patients receiving CPAP treatment lost 5.7 pounds more on average than patients not receving CPAP therapy.
March 24, 2019
A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.
Madeline Belk, PharmD, Discusses Oral Vancomycin as a First-Line CDI Therapy
Low Prevalence of Keratosis Pilaris in Patients with Atopic Dermatitis
Bruce Sands, MD: Efficacy of Mirikizumab for UC Treatment in LUCENT-1 Trial
